Jane Street Group LLC Lowers Stock Holdings in scPharmaceuticals Inc. (NASDAQ:SCPH)

Jane Street Group LLC cut its holdings in shares of scPharmaceuticals Inc. (NASDAQ:SCPH) by 46.2% during the third quarter, Holdings Channel reports. The firm owned 23,485 shares of the company’s stock after selling 20,206 shares during the quarter. Jane Street Group LLC’s holdings in scPharmaceuticals were worth $107,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the business. BNP Paribas Financial Markets boosted its holdings in scPharmaceuticals by 116.9% in the third quarter. BNP Paribas Financial Markets now owns 5,753 shares of the company’s stock valued at $26,000 after purchasing an additional 3,101 shares during the period. The Manufacturers Life Insurance Company acquired a new stake in scPharmaceuticals during the third quarter worth approximately $57,000. MetLife Investment Management LLC lifted its position in scPharmaceuticals by 135.0% in the third quarter. MetLife Investment Management LLC now owns 16,974 shares of the company’s stock valued at $77,000 after acquiring an additional 9,752 shares during the last quarter. Captrust Financial Advisors boosted its position in shares of scPharmaceuticals by 32.2% in the 3rd quarter. Captrust Financial Advisors now owns 18,539 shares of the company’s stock valued at $85,000 after purchasing an additional 4,513 shares during the period. Finally, Bank of New York Mellon Corp boosted its holdings in shares of scPharmaceuticals by 15.1% in the second quarter. Bank of New York Mellon Corp now owns 86,101 shares of the company’s stock valued at $375,000 after acquiring an additional 11,269 shares during the period. Institutional investors and hedge funds own 89.52% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the company. Craig Hallum lowered their price target on scPharmaceuticals from $16.00 to $12.00 and set a “buy” rating on the stock in a report on Thursday, November 14th. HC Wainwright reiterated a “buy” rating and issued a $18.00 target price on shares of scPharmaceuticals in a research note on Thursday, November 14th.

scPharmaceuticals Stock Down 3.7 %

SCPH stock opened at $3.38 on Wednesday. The stock has a market capitalization of $169.14 million, a PE ratio of -1.78 and a beta of 0.11. The company has a fifty day moving average of $3.54 and a 200-day moving average of $4.27. The company has a debt-to-equity ratio of 1.66, a quick ratio of 6.89 and a current ratio of 8.08. scPharmaceuticals Inc. has a one year low of $3.08 and a one year high of $6.54.

scPharmaceuticals Company Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.